Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers.

American journal of clinical oncology - 1 Apr 2022

Tan Elaine, Whiting Junmin, Knepper Todd, Xie Hao, Imanirad Iman, Carballido Estrella, Felder Seth, Frakes Jessica, Mo Qianxing, Permuth Jennifer B, Somerer Katelyn, Kim Richard, Anaya Daniel A, Fleming Jason B, Walko Christine, Sahin Ibrahim H

Abstract excerpt

INTRODUCTION: Homologous recombination mutations (HRM) have led to increased responses to platinum chemotherapy in pancreatic cancer. However, HRMs' role in nonpancreatic gastrointestinal (GI) cancers remains to be determined. Our objective was to evaluate the prognostic and predictive role of core (BRCA1, BRCA2, PALB2) and noncore HRM in nonpancreatic GI cancers receiving platinum therapy. MATERIALS AND METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Homologous Recombination

Share to Mutation

Share to Pancreatic Neoplasms

Share to Platinum

Share to Prognosis

Source

Identifiers

PMID: 35320814
DOI: 10.1097/COC.0000000000000901

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers.PMID 35320814Read ↗

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II TrialSemantic proximity Read ↗

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy durationSemantic proximity Read ↗

Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT databaseSemantic proximity Read ↗

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.Semantic proximity Read ↗

Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genesSemantic proximity Read ↗

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.Semantic proximity Read ↗

The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancerSemantic proximity Read ↗

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.Semantic proximity Read ↗

Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor ProgramSemantic proximity Read ↗

Germline Pathogenic Variants in Homologous Recombination Pathway Genes Are Frequent in Pancreatobiliary Ampullary Carcinoma.Semantic proximity Read ↗

Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in TaiwanSemantic proximity Read ↗

A mutational signature in gastric cancer suggests therapeutic strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.